Genentech, Inc.

Bantam Pharmaceutical, LLC

Oric Pharmaceuticals, Inc.

F. Hoffmann-la Roche Ag

Lea Constantineau-Forget

Stephane Ciblat

Chantal Grand-Maitre

Huifen Chen

Alan B Cooper

Matthew Volgraf

Elisia Villemure

Robin Larouche-Gauthier

Luce Lépissier

Francis Beaumier

Gerald W Shipps

Jack Alexander Terrett

Martin Dery

M Arshad Siddiqui

Claudio F Sturino

Nicolas Bruneau-Latour

Sanjay Srivastava

Chantal Grand-Maître

Martin Déry

Xiangyu Guo

Xiaohui Du

F Anthony Romero

Paul Gibbons

Jared Moore

Hiroyuki Kawai

Kejia Wu

Joanne Tan

Vu Linh Ly

Dilan Emine Polat

Daniel Gordon Michael Shore

Vibha Oza

Hugo De Almeida Silva

Vincent Albert

Amit Nayyar

Hong Wang

Chudi Ndubaku

Jae Hyuk Chang

Michael Luther

Jedd Levine

Brian Salvatore Safina

Matthew J Kostura

Stuart Ward

Daniel Shore

Aijun Lu

Arshad M Siddiqui

Matthew W Kostura

Chantal Grand-MAÎTRE

Martin DÉRY

Luce LÉPISSIER

Claudio Sturino

Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Polo like kinase 4 inhibitors

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R, Rand n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Oxadiazole transient receptor potential channel inhibitors

Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X, X, Z, Z, the ring system denoted by 'a', R, L, L, Q, L, R, L, R, L, and Rare as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.

Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases

The invention relates to methods of using compounds formula I: and pharmaceutically acceptable salts thereof wherein A, X, R, Rand n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts and N-oxides thereof, wherein X, X, Z, Z, the ring system denoted by 'a', R, A, L, A, L, L, Q, L, R, A, L, A, L, R, L, and Rare as described herein. In certain embodiments, compounds disclosed herein disrupt the eIF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.

Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formulae (Ia), (Ib), (Ic), (Id) and (Ie), in which R, L, L, Q, L, R, L, R, L, and Rare as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene. 

Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and/V-oxides thereof, wherein X, X, Z, Z, the ring system denoted by 'a', R, A, L, A, L, L, Q, L, R, A, L, A, L, R, L, and Rare as described herein. In certain embodiments, compounds disclosed herein disrupt the eIF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism. 

Growing community of inventors

Montreal, Canada

Lea Constantineau-Forget